AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital

AstraZeneca’s (AZN) partnership with CSPC Pharmaceutical to develop a small molecule that reduces Lp(a) levels and has “favorable” terms for CSPC’s preclinical agent, including $100M upfront plus $1.92B in milestones and royalties, reflects the significant potential of the LP(a) space, BMO Capital tells investors in a research note. The partnership reminds the firm that the Lp(a) space remains hot and BMO notes that Outperform-rated Silence Therapeutics (SLN) and Crispr Therapeutics (CRSP) are the only major genetic medicine players available for partnership in the space, with potential partners that could include Bayer (BAYRY), Alnylam (ALNY), Merck (MRK), Roche (RHHBY), Novo (NVO), and Bristol Myers (BMY).